Fifth Third Wealth Advisors LLC Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Fifth Third Wealth Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 13.5% in the third quarter, HoldingsChannel reports. The firm owned 19,775 shares of the company’s stock after purchasing an additional 2,350 shares during the quarter. Fifth Third Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $3,205,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of JNJ. Wrapmanager Inc. grew its position in Johnson & Johnson by 18.0% in the third quarter. Wrapmanager Inc. now owns 17,017 shares of the company’s stock worth $2,758,000 after acquiring an additional 2,601 shares in the last quarter. BIP Wealth LLC lifted its stake in shares of Johnson & Johnson by 10.7% in the 3rd quarter. BIP Wealth LLC now owns 7,481 shares of the company’s stock valued at $1,212,000 after purchasing an additional 722 shares during the last quarter. Prospera Financial Services Inc boosted its holdings in shares of Johnson & Johnson by 17.5% in the 3rd quarter. Prospera Financial Services Inc now owns 110,265 shares of the company’s stock worth $17,881,000 after purchasing an additional 16,428 shares during the period. Verity & Verity LLC raised its holdings in Johnson & Johnson by 0.7% during the 3rd quarter. Verity & Verity LLC now owns 96,035 shares of the company’s stock valued at $15,564,000 after buying an additional 644 shares during the period. Finally, OneAscent Financial Services LLC bought a new stake in Johnson & Johnson in the third quarter worth $1,542,000. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $154.77 on Tuesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a 50 day moving average price of $161.11 and a 200-day moving average price of $156.16. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The stock has a market capitalization of $372.63 billion, a PE ratio of 22.40, a PEG ratio of 2.74 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the prior year, the business earned $2.66 earnings per share. Johnson & Johnson’s revenue was up 5.2% on a year-over-year basis. Equities analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on JNJ shares. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Guggenheim raised their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Wolfe Research assumed coverage on Johnson & Johnson in a research note on Friday. They set an “outperform” rating and a $190.00 target price on the stock. Morgan Stanley raised their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Citigroup upped their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.94.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.